Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Baxter
Chinese Patent Office
US Department of Justice
Fuji
Healthtrust
Cipla
Teva

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,861,379

« Back to Dashboard

Which drugs does patent 5,861,379 protect, and when does it expire?

Patent 5,861,379 protects EGRIFTA and is included in one NDA.

This patent has twenty-four patent family members in twelve countries.
Summary for Patent: 5,861,379
Title: Chimeric fatty body-pro-GRF analogs with increased biological potency
Abstract:The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
Inventor(s): Ibea; Michel (Montreal, CA), Abribat; Thierry (Montreal, CA), Brazeau; Paul (Montreal, CA)
Assignee: Theratechnologies Inc. (Montreal, CA)
Application Number:08/702,114
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;

Drugs Protected by US Patent 5,861,379

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,861,379

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,939,386 Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency ➤ Sign Up
6,458,764 GRF analogs with increased biological potency ➤ Sign Up
6,020,311 GRF analogs with increased biological potency ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fish and Richardson
Cerilliant
Accenture
Healthtrust
Julphar
Moodys
Chubb
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.